Olsen Dag Rune, Bruland Oyvind S, Frykholm Gunilla, Norderhaug Inger Natvig
Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway.
Radiother Oncol. 2007 May;83(2):123-32. doi: 10.1016/j.radonc.2007.03.001. Epub 2007 May 11.
Proton therapy is an emerging treatment modality for cancer that may have distinct advantages over conventional radiotherapy. This relates to its ability to confine the high-dose treatment area to the tumour volume and thus minimizing radiation dose to surrounding normal tissue. Several proton facilities are currently operating or under planning world-wide - in the United States, Asia and Europe. Until now no systematic review assessing the clinical effectiveness of this treatment modality has been published.
A systematic review of published studies that investigated clinical efficacy of proton therapy of cancer.
We included 54 publications: 4 randomized controlled trials (RCTs) reported in 5 publications, 5 comparative studies and 44 case series. Two RCTs addressed proton irradiation as a boost following conventional radiation therapy for prostate cancer, where one demonstrated improved biochemical local control for the highest dose group without increased serious complication rates. Proton therapy has been used to treat a large number of patients with ocular tumours, but except for one low quality RCT, no proper comparison with other treatment alternatives has been undertaken. Proton therapy offers the option to deliver higher radiation doses and/or better confinement of the treatment of intracranial tumours in children and adults, but reported studies are heterogeneous in design and do not allow for strict conclusions.
The evidence on clinical efficacy of proton therapy relies to a large extent on non-controlled studies, and thus is associated with low level of evidence according to standard heath technology assessment and evidence based medicine criteria.
质子治疗是一种新兴的癌症治疗方式,可能比传统放疗具有明显优势。这与其将高剂量治疗区域局限于肿瘤体积从而使周围正常组织受辐射剂量最小化的能力有关。目前全球有几个质子治疗设施正在运行或正在规划中,分布在美国、亚洲和欧洲。到目前为止,尚未发表过评估这种治疗方式临床有效性的系统评价。
对已发表的研究进行系统评价,这些研究调查了质子治疗癌症的临床疗效。
我们纳入了54篇文献:5篇文献中报道了4项随机对照试验(RCT)、5项比较研究和44个病例系列。两项RCT将质子照射作为前列腺癌传统放疗后的增敏治疗,其中一项显示最高剂量组生化局部控制得到改善,且严重并发症发生率未增加。质子治疗已被用于治疗大量眼部肿瘤患者,但除了一项低质量的RCT外,未与其他治疗方案进行适当比较。质子治疗为儿童和成人颅内肿瘤提供了更高辐射剂量和/或更好治疗局限度的选择,但报道的研究设计各异,无法得出严格结论。
关于质子治疗临床疗效的证据在很大程度上依赖于非对照研究,因此根据标准的卫生技术评估和循证医学标准,证据水平较低。